AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Transgene

Regulatory Filings Jun 10, 2014

1715_iss_2014-06-10_f5bf9547-67e2-445e-bea6-71d3c92d54dc.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

Transgene Announces Participation in Upcoming Investor Events in France and US

Strasbourg, France, June 10, 2014 – Transgene today announced that management will participate in the following investor events:

"Village des Actionnaires": Stéphane Boissel, Executive Vice President and Chief Financial Officer, will participate in a thematic round table on the biotech sector. The event will be held on Thursday, June 12 at l'Espace Tête d'Or in Lyon, France. More information on the program can be found at: www.levillagedesactionnaires.com.

French Life Sciences Day: Philippe Archinard, Chairman and Chief Executive Officer, will give a corporate presentation on Thursday, June 26. The event will be held in New York, NY, USA, and is sponsored by France Biotech, the French association of biotechnology companies and their partners.

European Midcap Event "Spring": Stéphane Boissel will meet with investors on Thursday, June 26. The event will be held in Paris, France.

About Transgene

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene's programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology; this includes clinical-stage TG4001 for oropharyngeal cancer and TG1050 for hepatitis B in advanced pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.

Contacts:

Transgene Elisabetta Castelli, Director IR +33 (0)3 88 27 91 21

Laurie Doyle, Director IR US & Corporate Communications +1 (339) 832 0752

[email protected]

MC Services

Raimund Gabriel +49 89 210 228 30 [email protected]

Shaun Brown +44 207 148 5998 [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.